Meridian Bioscience, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Meridian Bioscience, Inc. (NasdaqGS: VIVO) violated federal securities laws by issuing materially false and misleading statements regarding the company’s business and operations. Meridian, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide.

Meridian Subsidiary’s Lead Tests May be Inaccurate

On May 17, 2017, the U.S. Food and Drug Administration (“FDA”) warned that lead tests made by Meridian’s subsidiary, Magellan Diagnostics, may be inaccurate. The warning covers all four of the company’s lead testing systems and is specific to tests performed on blood drawn from a vein, which “may provide results that are lower than the actual level of lead in the blood,” according to the FDA. The FDA – which is “aggressively investigating” the cause of this issue – recommends that laboratories and health care personnel discontinue using Magellan testing with venous blood samples, as lead poisoning can be easily missed. On this news, Meridian’s stock plunged 9.5% in morning trade on May 17, 2017.

Meridian Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, Robbins Arroyo LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of Shareholders

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: